Troels Jordansen, Glycostem Therapeutics, Oss, The Netherlands, discusses the development of the world’s first off-the-shelf NK cellular immunotherapy in acute myeloid leukemia patients and subsequent clinical trials involving oNKord® cellular therapy. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).